|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 1 (January 1), 1997:
pp. 227-234
Interleukin-6 Inhibits Fas-Induced Apoptosis and Stress-Activated Protein Kinase Activation in Multiple Myeloma Cells
By
Dharminder Chauhan,
Surender Kharbanda,
Atsushi Ogata,
Mitsuyoshi Urashima,
Gerrard Teoh,
Michael Robertson,
Donald W. Kufe, and
Kenneth C. Anderson
From the Divisions of Hematologic Malignancies and Cancer Pharmacology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02215.
 |
ABSTRACT |
Fas belongs to the family of type-1 membrane proteins that transduce apoptotic signals. In the present studies, we characterized signaling during Fas-induced apoptosis in RPMI-8226 and IM-9 multiple myeloma (MM) derived cell lines as well as patient plasma cell leukemia cells. Treatment with anti-Fas (7C11) monoclonal antibody (MoAb) induced apoptosis, evidenced by internucleosomal DNA fragmentation and propidium iodide staining, and was associated with increased expression of c-jun early response gene. We also show that anti-Fas MoAb treatment is associated with activation of stress-activated protein kinase (SAPK) and p38 mitogen-activated protein kinase (MAPK); however, no detectable increase in extracellular signal-regulated kinases (ERK1 and ERK2) activity was observed. Because interleukin-6 (IL-6) is a growth factor for MM cells and inhibits apoptosis induced by dexamethasone and serum starvation, we examined whether IL-6 affects anti-Fas MoAb-induced apoptosis and activation of SAPK or p38 MAPK in MM cells. Culture of MM cells with IL-6 before treatment with anti-Fas MoAb significantly reduced both DNA fragmentation and activation of SAPK, without altering induction of p38 MAPK activity. These results therefore suggest that anti-Fas MoAb-induced apoptosis in MM cells is associated with activation of SAPK, and that IL-6 may both inhibit apoptosis and modulate SAPK activity.
| |
INTRODUCTION |
MULTIPLE MYELOMA (MM) is characterized by the presence of malignant plasma cells predominantly localized in bone marrow (BM). The role of interleukin-6 (IL-6) as an autocrine and paracrine growth factor for MM cells is well established.1-7 Preliminary studies of IL-6 signal transduction in MM cell lines and MM patient cells suggest that the Ras dependent mitogen-activated protein kinase (MAPK) cascade mediates growth of MM cells.8 Moreover, abnormalities of cell cycle regulatory proteins, ie, RB and p16, may also play a role in IL-6 mediated MM cell growth.9,10
IL-6 has also been shown to be a survival factor for MM cells, since it inhibits apoptosis of MM cell lines and patient cells induced by serum starvation and dexamethasone.11,12 However, the signaling cascades involved in initiating programmed cell death in MM cells, evidenced by nuclear chromatin condensation and DNA fragmentation,13-19 have not been fully characterized. Specifically, triggering via Fas (APO-1/CD95) Ag, a transmembrane molecule belonging to the protein superfamily of tumor necrosis factor (TNF )/nerve growth receptors, can induce apoptosis in a variety of cell types.20-24 Recent studies have shown that Fas Ag is variably expressed on some purified plasma cell leukemia and MM cells as well as derived cell lines, and that crosslinking of Fas Ag induces apoptosis.25-27 Proposed mechanisms of resistance of MM cells to Fas-induced apoptosis include lack of cell surface expression of Fas Ag and high Bcl-2 expression in spite of Fas Ag expression. The sensitivity of purified MM cells and resistance of MM BM mononuclear cells (BMMCs) to Fas-triggered apoptosis, coupled with the ability of human serum to block Fas-induced apoptosis, suggest the presence of a soluble inhibitory factor.25 Although IL-6 has been shown to inhibit decadron-induced apoptosis in MM cells, at least in part by upregulating bcl-x1 expression,24,25,28 the effect of IL-6 on anti-Fas MoAb induced apoptosis and its mechanism of action has not been extensively characterized.
Signaling cascades involved in apoptosis are now being delineated. Specifically, previous studies in our laboratory have demonstrated that DNA damaging agents, ie, 1- -D-arabinofuranosylcytosine (ara-c) and ultraviolet (UV) light, induce DNA-fragmentation and induction of c-jun gene in myeloid leukemic cells.29-31 This finding suggests that activation of specific transcription factors in response to genotoxic stress may play a role in the regulation of programmed cell death. In addition, studies have demonstrated that c-Jun is phosphorylated at two serine residues (Ser63 and Ser73 ) in its amino-terminal transactivation domain by stress-activated protein kinase (SAPK) or c-Jun amino-terminal kinase (JNK), a member of the MAPK-related family of p54/46 serine/threonine kinases.32-34 Moreover, we and others have shown that stress stimuli, ie, ionizing radiation, TNF, sphingomyelinase and UV light activate SAPK.33,35-37 Finally, recent studies have shown that extracellular signal-regulated kinase (ERK), SAPK, and p38 MAPK all play an important role in regulating cell survival or apoptosis.38,39 To date, however, the role of these kinases in Fas-triggered apoptosis of MM cells has not been delineated.
In the present studies, we examined whether SAPK, p38 MAPK, ERK1, and ERK2 are activated during Fas-induced apoptosis of MM cells. Our studies show that triggering via Fas MoAb induces DNA fragmentation, c-jun expression, and activation of SAPK and p38 MAPK in MM cells without inducing ERK1 or ERK2. Because IL-6 is a growth factor for MM cells and is known to inhibit dexamethasone-induced apoptosis in MM cells,1-7,11,12 we also studied the effect of IL-6 pretreatment of MM cells on Fas-induced DNA fragmentation as well as SAPK and p38 MAPK activation. Pretreatment of cells with IL-6 significantly inhibits both DNA fragmentation and SAPK activity induced via Fas, without altering p38 MAPK. Our studies therefore suggest that IL-6 can modulate Fas-triggered apoptosis and SAPK activation in MM cells.
| |
MATERIALS AND METHODS |
Cell Culture
The human MM cell lines RPMI-8226 and IM9 (ATCC, Rockville, MD) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, St Louis, MO), 100 U/mL penicillin (pen), 100 mg/mL streptomycin (strep) and 2 mmol/L L-glutamine (GIBCO, Grand Island, NY). Mononuclear cells were isolated from the peripheral blood of a patient with plasma cell leukemia (PCL) by Ficoll-Hypaque density gradient centrifugation and incubated with HB7 (anti-CD38) monoclonal antibody (MoAb)-biotin-streptavidin and 2H4 (anti-CD45RA) MoAb-fluorescein isothiocyanate on ice. Tumor cells (96 ± 2% CD38+CD45RA-) were isolated using an Epics C Cell Sorter (Coulter Electronics, Hialeah, FL), washed, and resuspended in RPMI-1640 media containing 10% FBS, 2 mmol/L L-glutamine, 100 U/mL Pen, and 100 U/mL Strep. Cells were treated with either medium or with 7C11 anti-Fas MoAb (1:800)23 for the indicated intervals prior to analysis for apoptosis, Northern blotting for c-jun mRNA, as well as in vitro SAPK, p38 MAPK, ERK1, and ERK2 assays. In some experiments, MM cells were treated with IL-6 (100 ng/mL) for 3 to 4 hours before culture with anti-Fas MoAb.
Determination of Apoptosis
Two different methods were used to confirm anti-Fas-induced apoptosis in MM cells.
DNA fragmentation assays.
Genomic DNA was isolated from RPMI-8226, IM9, and PCL cells as previously described.40 Briefly, 1 to 2 × 106 cells were washed two times with phosphate buffered saline (PBS) and lysed in buffer (100 mmol/L NaCl, 10 mmol/L Tris-HCL pH 8.0, 25 mmol/L EDTA, 0.5% sodium dodecyl sulfate [SDS], and 0.1 mg/mL proteinase K) at 37°C for 18 hours. DNA was extracted with an equal volume of phenol/chloroform (1:1) and precipitated at -70°C for 2 hours with 0.3 mol/L NaAcetate and 2.5 volume of absolute ethanol. DNA pellets were resuspended in 20 L of 10 mmol/L Tris (pH 7.8) 1 mmol/L EDTA buffer and incubated for 1 hour at 37°C with 1 µg/mL RNase (Boehringer Mannheim Corp, Indianapolis, IN).
DNA-end labeling was performed as previously described.41 Briefly, 0.5 to 1.0 µg of DNA was treated with 5 U of Klenow polymerase with 0.5 µCi of [ 32P]-dCTP in reaction mixture (Tris-HCL pH 7.5, 5 mmol/L MgCl2 ) for 10 minutes at room temperature and terminated by addition of 10 mmol/L EDTA. Unincorporated nucleotides were removed by three consecutive precipitation cycles with ammonium acetate/isopropanol, and labeled DNA was resuspended in 10 mmol/L Tris-HCL (pH 7.5) 1 mmol/L EDTA. Labeled DNA probes were electrophoresed for 2 to 3 hours at 90 V on 1.8% agarose gels, which were dried and exposed for autoradiography.
Flow cytometric analyses.
1 ×106 cells were washed twice with cold PBS and fixed by the addition of 40% cold ethanol at 4°C for 30 minutes. Cells were then washed with PBS and treated with RNase (50 µg/mL) for 45 minutes at 37°C. After treatment with RNase, cells were washed with PBS and resuspended in PBS containing 15 µg/mL propidium iodide. Flow cytometric analyses was done using FACScan (Becton Dickinson, San Diego, CA).
RNA Isolation and Northern Blot Analysis
Total cellular RNA was purified using the guanidine isothiocyanate cesium chloride technique as previously described.42 Briefly, total cellular RNA (20 µg/lane) was subjected to electrophoresis through a 1% agarose/2.2 mol/L formaldehyde gel, transferred to nitrocellulose filters, and hybridized to one of the following 32P-labeled DNA probes: (1) the 1.8 kb BamHI/EcoRI insert of a human c-jun gene purified from a pBluescript SK(+) plasmid43; and (2) the 2.0 kb Pst I insert of a chicken -actin gene purified from the pA1 plasmid.44 Hybridizations were performed at 42°C for 24 hours in 50% (vol/vol) formamide, 2 × SSC (SSC: 0.15 mol/L sodium chloride, 0.015 mol/L sodium citrate), 1 × Denhardt's solution, 0.1% (wt/vol) SDS, and 200 µg/mL salmon sperm DNA. The filters were washed twice, first in 2 × SSC-0.1% SDS at room temperature and next in 0.1 × SSC-0.1% SDS at 60°C for 30 minutes, and then exposed to Kodak X-Omat XAR film (Eastman Kodak, Rochester, NY) using an intensifying screen. The autoradiograms were scanned using an LKB produkter (Bromma, Sweden) Ultrascan XL laser densitometer and analyzed with the Gelscan software package. Signal intensity was determined in a linear range and normalized to that for actin.
Fusion Protein Binding Assays
Cells (2 to 3 × 107) were washed with PBS and lysed in 1 mL of lysis buffer (20 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 15 mmol/L NP-40, 1 mmol/L sodium vanadate, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L DTT, and 10 mg/mL of leupeptin and aprotinin). After incubation on ice for 30 minutes, insoluble material was removed by centrifugation at 14,000 rpm for 10 minutes at 4°C. Lysates were incubated with 5 mg immobilized GST or GST-Jun (2-100)fusion protein for 2 hours at 4°C. GST-Jun fusion protein was prepared as previously described.45 Protein complexes were washed with lysis buffer and incubated in kinase buffer (20 mmol/L HEPES, pH 7.0, 10 mmol/L MgCl2 , and 10 mmol/L MnCl2 ) containing [-32P]ATP for 15 minutes at 30°C. Reactions were terminated by boiling in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, and phosphorylated proteins analyzed by SDS-PAGE, Coomassie blue staining, and autoradiography.
Immune Complex Kinase Assays
Assays were performed as previously described.46 Lysates were precleared by incubating with 5 mg/mL rabbit-antimouse IgG for 1 hour at 4°C, followed by a 30 minutes incubation with protein A-Sepharose. Supernatants were incubated with either preimmune rabbit serum or specific antibodies for SAPK or ERK1/ERK2 (Santa Cruz Biotechnology, San Diego, CA) or p38 MAPK (provided by Dr Roger Davis, University of Massachusetts Medical School, Worcester) for 2 hours at 4°C before the addition of protein A-Sepharose for 1 hour. Immune complexes were washed three times with lysis buffer, once with kinase buffer, and resuspended in kinase buffer containing 1 mCi/mL [-32P]ATP (3,000 ci/mmol; New England Nuclear, Boston, MA) and GST-Jun(2-100) or GST-ATF2 (provided by Dr Roger Davis) or myelin basic protein (MBP) substrate. The reaction was incubated for 15 minutes at 30°C and terminated by the addition of SDS sample buffer. The proteins were analyzed by SDS-PAGE, Coomassie blue staining, and autoradiography.
Phenotypic Analysis of MM Cells
Cells were examined for the expression of Fas Ag before and after culture for 3 to 4 hours with IL-6 (100 ng/mL) using 7C11 anti-Fas MoAb and indirect immunofluorescence and flow cytometric analysis, as in previous studies.6 Antibody-coated cells were enumerated by flow cytometric analysis using an EPICS V cell sorter (Coulter Electronics).
| |
RESULTS |
Anti-Fas MoAb Induces Apoptosis in MM Cells
To test for Fas-triggered apoptosis, RPMI-8226 MM cells were cultured in media alone or with anti-Fas MoAb for 3, 6, and 9 hours. DNA cleavage was analysed by agarose gel electrophoresis of the 32P-labeled genomic DNA. Low to undetectable DNA clevage was observed in the cells cultured in media alone (Fig 1A). In contrast, exposure to anti-Fas MoAb resulted in significant clevage of DNA into oligonucleosomal fragments of approximately 200 bp. This pattern was most prominent after 6 and 9 hour culture with anti-Fas MoAb; longer periods of exposure to anti-Fas MoAb (24 hours and 48 hours) resulted in diffuse DNA degradation. Treatment of IM-9 MM cells and PCL patient cells with anti-Fas MoAb for 6 hours and 9 hours also induced apoptosis, evidenced by DNA-ladder formation (data not shown). In contrast, incubation of RPMI-8226, IM-9, and PCL cells with an isotype matched control MoAb did not cause DNA-laddering.
View larger version (20K):
[in this window]
[in a new window]
| Fig 1.
(A) 7C11 anti-Fas MoAb induces DNA fragmentation in RPMI 8226 MM cells. Cells were cultured in media alone and for the indicated times with 5 µg/mL of 7C11 anti-Fas MoAb. Genomic DNA was isolated, end-labeled with 0.5 mCi of [32-P]-dCTP, and analyzed by 1.8% agarose gel electrophoresis. MW, molecular weight markers (123-bp ladders and HindIII digest of l-DNA). (B) Quantification of anti-Fas-MoAb induced apoptosis in RPMI-8226 MM cells was performed by using propidium iodide staining technique. Cells were treated with anti-Fas MoAb for the indicated time intervals and stained with propidium iodide; percentage of apoptotic cells was analyzed by FACS. "C" represents control cells.
|
|
Apoptosis was further analyzed by FACS analysis. Cells were treated with anti-Fas MoAb for the indicated time periods and then stained with propidium iodide; percentage of apoptotic cells was determined by flow cytometric analyses. Treatment of RPMI-8226 MM cells with anti-Fas MoAb for 48 hours induced a significant increase in percentage of apoptotic cells (73% ± 5%, three independent experiments) (Fig 1B).
Anti-Fas MoAb Induces c-jun mRNA in MM Cells
Because our previous studies showed that c-jun, an early response gene, is induced during apoptosis triggered by ara-C,30 we in the present study measured expression of c-jun gene during Fas-induced apoptosis in RPMI 8226 MM cells. Low to undetectable levels of c-jun transcripts were observed in cells cultured in media alone (Fig 2). In contrast, treatment of MM cells with anti-Fas MoAb induced c-jun transcript as early as 1 hour; densitometry showed that c-jun mRNA levels peaked at 6 hours (8.2 ± 0.5-fold increase) and declined thereafter (Fig 2 and data not shown). There were no associated changes in -actin mRNA.
View larger version (47K):
[in this window]
[in a new window]
| Fig 2.
Effect of anti-Fas MoAb on induction of early response gene c-jun in RPMI 8226 MM cells. Cells were either cultured in media alone or treated with anti-Fas MoAb for the indicated times. Total cellular RNA (20 µg/lane) was hybridized to 32P-labeled c-jun and actin probes.
|
|
Effect of Anti-Fas MoAb Treatment on the Activation of SAPK, p38 MAPK, and ERK-1
We next assayed for Fas-induced activation SAPK, p38 MAPK, and ERK-1 since previous studies have shown a role of these kinases in regulation of growth and apoptosis.38,39 To assay for induction of SAPK activity in MM cells, RPMI-8226 MM cells were exposed to anti-Fas MoAb and harvested at 15, 30, and 60 minutes; lysates of control and anti-Fas MoAb-treated cells were subjected to affinity chromatography with GST-Jun (2-100) fusion protein and assayed for c-Jun phosphorylation. As shown in Fig 3A, adsorbates from anti-Fas MoAb-treated MM cells demonstrated increased Jun kinase activity compared to that in control cells. c-Jun kinase activity was detectable at 15 minutes and maximal at 60 minutes. To determine whether the Fas-induced Jun kinase activity is due to parallel increases in SAPK activity, we assayed anti-SAPK immunocomplexes for phosphorylation of GST-Jun. Anti-Fas MoAb induced activation of SAPK at 30 minutes, which peaked at 60 minutes (Fig 3B). Finally, we assayed for induction via Fas of p38 MAPK, ERK1 and ERK2 activities. Anti-Fas MoAb induced p38 MAPK activity at 15 minutes, which peaked at 60 minutes, evidenced by phosphorylation of GST-ATF2 by p38 MAPK immunocomplexes of Fas-treated cells; no similar changes were evident in control cells (Fig 3C). In contrast, Fas did not induce any significant change in ERK1 or ERK2 activity, assayed by phosphorylation of MBP substrate by ERK1 or ERK2 immunocomplexes of Fas-treated cells (Fig 3D and data not shown). Coomassie blue staining confirmed equal protein loading within each lane (data not shown).
View larger version (39K):
[in this window]
[in a new window]
| Fig 3.
Anti-Fas MoAb induces activation of SAPK and p38 MAP kinase. (A) RPMI 8226 MM cells were treated with 5 µg/mL of anti-Fas MoAb for 15, 30, and 60 minutes. Cell lysates prepared from control cells (media alone) and anti-Fas MoAb-treated cells were incubated with glutathione-sepharose beads containing 5 µg of GST-Jun (2-100) for 2 hours. The resulting protein complexes were washed and then incubated in kinase buffer containing GST-Jun fusion protein and [-32P]ATP for 15 minutes at 30°C. The phosphorylated proteins were resolved by 10% SDS-PAGE, stained with Coomassie blue, dried, and analyzed by autoradiography. Lysates from control and anti-Fas MoAb-treated RPMI-8226 cells were also immunoprecipitated with anti-SAPK Ab (B), anti-p38 MAP kinase Ab (C), or anti-ERK-1 Ab (D). Immune complex kinase assays were performed by addition of GST-Jun (B), GST-ATF-2 (C), or MBP (D) and [32P]ATP and incubation for 15 minutes at 30°C. The phosphorylated proteins were resolved by 10% SDS-PAGE and analyzed by Coomassie blue staining and autoradiography. Anti-SAPK immunocomplexes prepared from control and anti-Fas treated IM-9 (E) and PCL (F ) cells were also assayed for phosphorylation of GST-Jun.
|
|
Additional experiments were performed using IM-9 and patient PCL cells. Cell lysates from unstimulated and anti-Fas treated cells were subjected to immunoprecipitation with anti-SAPK Ab, and anti-SAP immunocomplexes were assayed for phosphorylation of GST-Jun. Triggering via Fas MoAb induced activation of SAPK in both IM-9 (Fig 3E) and PCL (Fig 3F ) cells.
IL-6 Inhibits Fas-Induced DNA Fragmentation in MM Cells
IL-6 triggers a twofold increase in stimulation index of RPMI-8226 MM cells.6 Recent studies have also shown that IL-6 prevents apoptosis in MM cells and B cell hybridomas induced by dexamethasone, factor deprivation and serum starvation11,12; therefore, we determined whether IL-6 inhibits RPMI-8226 MM cell apoptosis triggered via Fas. RPMI-8226 MM cells were cultured with IL-6 (100 ng/mL) for 3 to 4 hours before addition of anti-Fas MoAb for 6 hours; a substantial decrease in the nucleosomal DNA-laddering was evident in cells treated with IL-6 before culture with anti-Fas MoAb, compared to cells cultured in media or with anti-Fas MoAb (Fig 4C). This inhibition of apoptosis was not associated with cell surface changes in the percentage or intensity of Fas Ag expression on RPMI-8226 cells cultured with IL-6 (data not shown).
View larger version (39K):
[in this window]
[in a new window]
| Fig 4.
Effect of IL-6 pretreatment on anti-Fas MoAb-induced SAPK and p38 MAPK activation, as well as DNA fragmentation, in RPMI 8226 MM cells. Cells were cultured in media alone or pretreated with IL-6 as indicated before anti-Fas MoAb treatment. Cell lysates were immunoprecipitated with anti-SAPK Ab (A) or anti-p38 MAPK Ab (B). The resulting protein complexes were washed and then incubated in kinase buffer containing GST-Jun and [-32P]ATP for 15 minutes at 30°C. The phosphorylated proteins were resolved by 10% SDS-PAGE, stained with Coomassie blue, dried, and analyzed by autoradiography. (C) Cells were cultured in either media alone or treated with 100 ng/mL of IL-6 for 3 to 4 hours before stimulation with anti-Fas MoAb for 6 hours. Genomic DNA was isolated, end-labeled with [32P]ATP, and analyzed by 1.8% agarose gel electrophoresis. MW, molecular weight markers (123-bp ladders and HindIII digest of l-DNA).
|
|
IL-6 Inhibits Induction of SAPK, But Not of p38 MAPK, Triggered via Fas in MM Cells
To test whether the anti-apoptotic effect of IL-6 in Fas-induced MM cell death involves regulation of SAPK and p38 MAPK, we determined whether culture of MM cells with IL-6 altered subsequent Fas-induced phosphorylation of GST-Jun (SAPK activity) or GST-ATF2 (p38 MAPK activity). MM cells were cultured in media or with IL-6 for 3 to 4 hours before addition of anti-Fas MoAb, and cell lysates were subjected to immunoprecipitation with anti-p54 SAPK Ab followed by assay for GST-Jun phosphorylation, or with anti-p38 MAPK Ab followed by GST-ATF2 phosphorylation. As shown in Fig 4A, treatment of MM cells with IL-6 alone did not induce SAPK activation. However, SAPK activation was significantly reduced in MM cells treated with IL-6 before culture with anti-Fas MoAb, compared to controls. No similar effects of IL-6 on Fas-induced p38 MAPK activation in MM cells was observed (Fig 4B). Coomassie blue staining confirmed equal loading of protein in each individual lane (Fig 4A, middle band and 4B, lower band).
| |
DISCUSSION |
In the present study, we characterized the signaling mechanism involved in Fas-induced apoptosis of RPMI-8226 MM cells. Anti-Fas MoAb induced DNA fragmentation, which was associated with increased c-jun transcripts, as well as increased SAPK and p38 MAPK activity. Importantly, IL-6 significantly reduced both DNA fragmentation and SAPK activity triggered via Fas. Therefore, our studies suggest that anti-Fas MoAb-induced activation of SAPK is associated with apoptosis, and that IL-6 can abrogate both SAPK activation and apoptosis.
Multiple studies have shown that triggering via Fas(APO-1) Ag induces apoptosis in various cell types.20-24 Fas Ag is a 45-kD type I membrane protein of the TNF/nerve growth factor receptor superfamily, which also includes CD40, CD30, CD27, and OX40.21,22 Fas ligand is a 40 kD type II membrane protein of the TNF family, which includes TNF- , TNF-, CD40 ligand, and CD30 ligand.47-49 Shima et al26 have previously reported that five human MM cell lines and the majority of freshly isolated patient MM cells express Fas Ag, and that anti-Fas MoAb treatment triggered loss of cell volume, membrane blebbing, fragmentation of nuclei, and condensed chromatin in some MM cell lines and MM patient samples. Hata et al29 have similarly found Fas Ag to be present on the majority of MM cell lines and patient cells; anti-Fas MoAb triggered apoptosis, confirmed by morphologic analysis alone and/or DNA electrophoresis in some cases. Finally, Westendorf et al25 have demonstrated apoptosis, confirmed both by DNA fragmentation and morphological changes, in some human MM cell lines and patient samples.25 The present studies showed anti-Fas MoAb induced fragmentation of MM cell DNA into multiples of nucleosome sized fragments, changes in chromatin structure characteristic of apoptosis or programmed cell death.50
The signaling mechanism initiated by Fas is not yet delineated. Mutational studies of Fas have shown that an intracellular domain, homologous to a region of the TNF receptor, is essential for Fas-mediated cell death.51 However, the intracellular region of the Fas molecule has no consensus sequence for kinases or phosphatases. A possible mechanism of Fas signaling is via acid sphingomyelinase, analogous to TNF52: TNF induces acid sphingomyelinase activity, resulting in increased production of ceramide which induces apoptosis.53 Alternatively, Fas-mediated apoptosis may involve an IL-1 converting enzyme-like protease.54,55 Recent studies which show that UV light, ionizing radiation, and ceramide activate SAPK activity33,35-37,39 and show a role for SAPK and p38 MAPK in apoptosis38,39 suggest their posible role in Fas-related apoptosis. Our present studies in MM cells also suggest involvement of SAPK and p38 MAPK in apoptosis. They demonstrate that anti-Fas MoAb induced both DNA fragmentation and increased c-jun mRNA levels in MM cells, as well as c-Jun phosphorylation (confirming SAPK activation) and GST-ATF2 phosphorylation (confirming p38 MAPK activation). Moreover, they further support the view that initiation and continuation of apotosis involves activation of transcription factors56,57: phosphorylation of c-Jun upregulates c-jun transcription through AP-1 binding,58,59 and the induction of c-jun expression observed in our study may therefore be mediated by the SAPK signaling pathway.
In previous reports, resistance of MM cells to Fas-related apoptosis has been attributed to BCL-2 expression. For example, the single MM cell line found by Hata et al to be resistant to anti-Fas MoAb treatment despite its cell surface Fas Ag expression highly expressed BCL-2.27 However, others have found BCL-2 expression to be similar in both Fas-sensitive and Fas-resistant MM cell lines,26 suggesting that alternative mechanisms may confer protection against Fas-related apoptosis. In our preliminary studies, anti-Fas MoAb treatment downregulated expression of BCL-2 in RPMI-8226 MM cells, further supporting a protective mechanism other than BCL-2. Importantly, Westendorf et al25 found resistance of MM cells to anti-Fas MoAb-triggered apoptosis to be related either to the lack of cell surface Fas Ag expression; or to a soluble factor present in serum, since MM BMMCs were resistant and purified MM cells were sensitive to anti-Fas MoAb treatment.25
Prior studies have shown that IL-6 is one such soluble factor which can inhibit apoptosis of MM cells induced by Fas or other stimuli. Specifically, studies of MM cell lines and patient MM cells have shown that IL-6 inhibits apoptosis triggered by serum starvation or dexamethasone, but not that stimulated by doxorubicin or etoposide.11,12 Because IL-6 decreased BCL-2 expression in these MM cell lines, its anti-apoptotic effects cannot be directly related to BCL-2. Moreover, Schwarze and Hawley28 have shown that IL-6 mediated suppression of apoptosis in IL-6 dependent B9 cells does not involve induction of endogenous BCL-2 expression, but rather is associated with upregulation of cellular BCL-x mRNA and BCL-x protein. In their study, very high levels of BCL-2 in B9 cells, achievable only using retroviral or bovine papilloma virus-based vectors, suppressed apoptotic death induced by IL-6 deprivation. Therefore, to date, the anti-apoptotic effect of IL-6 on MM cells is not attributable to its effects on BCL-2. The importance of BCL-2 for in vivo survival of MM cells has also been questioned, since recent studies have found higher percentages of BCL-2 positive cells in patients with a long survival, compared to patients with refractory MM and short survival.60
In the present study, we also show that IL-6 is one soluble factor inhibiting apoptosis of MM cells triggered by Fas. In contrast to studies by Hata et al27 in which IL-6 (1 ng/mL) inhibited apoptosis in only a single MM patient sample and in no MM cell lines, we showed inhibition of MM cell apoptosis using 100 ng/mL IL-6. Inhibition of apoptosis at higher IL-6 concentrations in vitro observed in our study suggests that the increased in vivo IL-6 serum levels in patients with advanced stages of disease61-63 may not only mediate tumor cell growth, but also enhance tumor cell survival. Our finding that IL-6 pretreatment alters anti-Fas-MoAb induced SAPK activity and apoptosis without altering p38MAPK activity suggests that IL-6 may act on upstream events involved in activating SAPK, and not p38MAPK. Previous studies in MM and other cells have shown that IL-6 can initiate growth via the Ras dependent MAPK cascade: sequential activation of Shc, Grb2, Sos, Ras, Raf, MEK, and MAPK.8,64-67 In addition, Billadeau et al67 have also reported that expression of mutant ras in the IL-6 dependent ANBL-6 MM cell line facilitates growth in the absence of IL-6 and suppresses apoptosis. Finally, recent studies have shown that activation of ERK signaling pathways can inhibit apoptosis, and conversely, that inactivation of ERK signaling along with activation of SAPK or p38MAPK may be critical for apoptosis.38 These studies, coupled with the present report, suggest that IL-6 may exert an anti-apoptotic effect in MM cells by modulating the Ras-Raf-MAPK signaling cascades. Further characterization of the mechanism whereby IL-6 inhibits apoptosis in MM cells, including abrogation of SAPK activation, may not only provide clues to basic growth control in MM, but also offer new treatment strategies.
| |
FOOTNOTES |
Submitted May 7, 1996;
accepted August 12, 1996.
Supported by National Institutes of Health Grant No. CA 50947 and the Kraft Family Research Fund.
Address reprint requests to Kenneth C. Anderson, MD, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1.
Kawano M,
Hirano T,
Matsuda T,
Taga T,
Horii Y,
Iwato K,
Asaoka H,
Tang O,
Tanaka H,
Kuramoto A,
Kishimoto T:
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma.
Nature
332:83,
1988[Medline]
[Order article via Infotrieve]
2.
Klein B,
Zhang X,
Jourdan M,
Content J,
Houssiau F,
Aarden L,
Piechaczyk M,
Bataille R:
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.
Blood
73:517,
1989[Abstract/Free Full Text]
3.
Lichtenstein A,
Berenson J,
Norman D,
Chang M-P,
Carlile A:
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.
Blood
74:1266,
1989[Abstract/Free Full Text]
4.
Anderson KC,
Jones RC,
Morimoto C,
Leavitt P,
Barut B:
Response of purified myeloma cells to hematopoietic growth factors.
Blood
73:1915,
1989[Abstract/Free Full Text]
5.
Caligaris-Cappio F,
Bergui L,
Gregoretti MG,
Gaidano G,
Gaboli M,
Schena M,
Zallone AZ,
Marchisio PC:
Role of bone marrow stromal cells in the growth of human multiple myeloma.
Blood
77:2688,
1991[Abstract/Free Full Text]
6.
Barut BA,
Zon LI,
Cochran MK,
Paul SR,
Chauhan D,
Mohrbacher A,
Fingeroth J,
Anderson KC:
Role of interleukin-6 in the growth of myeloma derived cell lines.
Leuk Res
16:951,
1992[Medline]
[Order article via Infotrieve]
7.
Klein B,
Zhang XG,
Yang LZ,
Bataille R:
Interleukin-6 in human multiple myeloma.
Blood
85:863,
1995[Free Full Text]
8. Ogata A, Chauhan D, Urashima M, Teoh G, Hatziyanni M, Vidriales MB, Schlossman RL, Anderson KC: Interleukin-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activatied protein kinase cascade. (submitted)
9. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phophorylation of Retinoblastoma protein. Blood (in press)
10. Urashima M, Teoh G, Ogata A, Chauhan D, Sugimoto Y, Kaihara C, Matsuzaki M, Hoshi Y, DeCaprio JA, Anderson KC: CDKN2(p16INK4A) protein expression is associated with interleukin-6 mediated multiple myeloma cell growth. 88:2219, 1996
11.
Lichtenstein A,
Tu Y,
Fady C,
Vescio R,
Berenson J:
Interleukin-6 inhibits apoptosis of malignant plasma cells.
Cell Immunol
162:248,
1995[Medline]
[Order article via Infotrieve]
12.
Hardin J,
Macleod S,
Grigorieva I,
Chang R,
Barlogie B,
Xiao H,
Epstein J:
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood
84:3063,
1994[Abstract/Free Full Text]
13.
Willie AH,
Kerr JFR,
Currie AR:
Cell death: The significance of apoptosis.
Int Rev Cytol
68:251,
1980[Medline]
[Order article via Infotrieve]
14.
Collins RJ,
Verscher LA,
Harmon BV,
Prentice RL,
Pope JH,
Kerr JF:
Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro.
Br J Haematol
71:343,
1989[Medline]
[Order article via Infotrieve]
15.
Raff MC:
Social control on cell survival and cell death.
Nature
356:397,
1992[Medline]
[Order article via Infotrieve]
16.
Kouy MJ,
Boudurant MC:
Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.
Science
248:378,
1990[Abstract/Free Full Text]
17.
Williams GT,
Smith CA,
Spooner E,
Dexter TM,
Taylor DR:
Haematopoietic colony stimulating factors promote cell survival by suppressing apoptosis.
Nature
343:76,
1990[Medline]
[Order article via Infotrieve]
18. Kerr JFR, Harmon BV: Definition and incidence of apoptosis: A historical perspective, in Tomeri LD, Cope FO (eds): Current Communications 3-Cell and Molecular Biology. Apoptosis: The Molecular basis of Cell Death. Cold Spring Harbor, NY, Cold Spring Laboratory, 1991, p 5
19.
Cotter TG,
Lennon SV,
Glynn JG,
Martin SJ:
Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells.
Anticancer Res
10:1153,
1990[Medline]
[Order article via Infotrieve]
20.
Yonehara S,
Ishi A,
Yonehara M:
A cell-killing monoclonal antibody (anti-Fas) to a surface antigen codownregulated with the receptor of tumor necrosis factor.
J Exp Med
181:1747,
1989
21.
Itoh N,
Yonehara A,
Ishi M,
Mizushima SI,
Sameshima M,
Hase A,
Seto Y,
Nagata S:
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.
Cell
66:233,
1991[Medline]
[Order article via Infotrieve]
22.
Oehm A,
Behrmann I,
Falk W,
Pawlita M,
Maier G,
Klas G,
Li-Weber CM,
Richards S,
Dhein J,
Trauth BC,
Ponsting H,
Krammer PH:
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.
J Biol Chem
267:10709,
1992[Abstract/Free Full Text]
23.
Robertson MJ,
Manley TJ,
Pichert G,
Cameron C,
Cochran KJ,
Levine H,
Ritz J:
Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.
Leuk Lymph
17:51,
1995[Medline]
[Order article via Infotrieve]
24.
Suda T,
Takashi T,
Goldstein P,
Nagata S:
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
Cell
75:1169,
1993[Medline]
[Order article via Infotrieve]
25.
Westerndorf JJ,
Lammeret J,
Jelinek DF:
Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.
Blood
85:3566,
1995[Abstract/Free Full Text]
26.
Shima Y,
Nishimoto N,
Ogata A,
Fuji Y,
Yoshizaki K,
Kishimoto T:
Myeloma cells express Fas antigen/APO-1(CD-95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
Blood
85:757,
1995[Abstract/Free Full Text]
27.
Hata H,
Hiromitsu M,
Takeya M,
Yoshida M,
Sonoki T,
Nagasaki A,
Kuribayashi N,
Kawano F,
Takatsuki K:
Expression of Fas/APO-1 (CD 95) and apoptosis in tumor cells from patients with plasma cell disorders.
Blood
86:1939,
1995[Abstract/Free Full Text]
28.
Schwarze MMK,
Hawley RG:
Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated upregulation of bcl-xl.
Cancer Res
55:2262,
1995[Abstract/Free Full Text]
29.
Sherman M,
Stone R,
Datta R,
Bernstein S,
Kufe D:
Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells.
J Biol Chem
265:3320,
1990[Abstract/Free Full Text]
30.
Gunji H,
Kharbanda S,
Kufe D:
Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1--D-arabinofuranosylcytosine.
Cancer Res
51:741,
1991[Abstract/Free Full Text]
31.
Devary Y,
Gottleib RA,
Lau LF,
Karin M:
Rapid and preferential activation of the c-jun gene during the mammalian UV response.
Mol Cell Biol
11:2804,
1991[Abstract/Free Full Text]
32.
Kyriakis JM,
Benerjee P,
Nikolakaki E,
Dai T,
Rubie EA,
Ahmad MF,
Avruch J,
Woodgett JR:
The stress-activated protein kinase subfamily of c-Jun kinases.
Nature
369:156,
1994[Medline]
[Order article via Infotrieve]
33.
Derijard B,
Hibi M,
Wu IH,
Barret T,
Su B,
Deng T,
Karin M,
Davis RJ:
JNK1: A protein kinase stimulated by UV light and H-Ras that binds and phosphorylates the c-Jun activation domain.
Cell
76:1025,
1994[Medline]
[Order article via Infotrieve]
34.
Hibi M,
Lin A,
Smeal T,
Minden A,
Karin M:
Identification of an oncoprotein and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.
Genes Dev
7:2135,
1993[Abstract/Free Full Text]
35.
Kharbanda S,
Ren R,
Pandey P,
Shafman TD,
Feller SM,
Wechselbaum RR,
Kufe DW:
Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.
Nature
376:785,
1995[Medline]
[Order article via Infotrieve]
36.
Kharbanda S,
Saleem A,
Shafman T,
Emoto Y,
Taneja N,
Rubin E,
Weichselbaum R,
Woodgett J,
Avruch J,
Kyriakis J,
Kufe D:
Ionizing radiation stimulates a Grb2-mediated association of the stress-activated protein kinase with phosphatidylinositol 3-kinase.
J Biol Chem
270:18871,
1995[Abstract/Free Full Text]
37.
Roy C,
Brown D,
Little JE,
Valentine BK,
Walker PR,
Sikorska M,
Leblanc J,
Caly N:
The topoisomerase II inhibits teniposide (VM-26) induced apoptosis in unstimulated mature murine lymphocytes.
Exp Cell Res
200:416,
1992[Medline]
[Order article via Infotrieve]
38.
Xia Z,
Dickens M,
Raingeaud J,
Davis RJ,
Greenberg ME:
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science
270:1326,
1995[Abstract/Free Full Text]
39.
Verheij M,
Bose R,
Lin XH,
Yao B,
Jarvis WD,
Grant S,
Birrer MJ,
Szabo E,
Zon LI,
Kyriakis JM,
Friedman AH,
Fuks Z,
Kolesnick RN:
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.
Nature
380:75,
1996[Medline]
[Order article via Infotrieve]
40.
Tian Q,
Streuli M,
Saito H,
Schlossman SF,
Anderson P:
A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells.
Cell
67:629,
1993
41.
Frank R:
A simple and rapid method for detection of apoptosis in human cells.
Nucleic Acids Res
20:5243,
1992[Free Full Text]
42.
Chauhan D,
Kharbanda S,
Uchiyama H,
Urashima M,
Sen J,
Fuguso R,
Kufe DW,
Anderson KC:
Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen.
Blood
84:2243,
1994[Abstract/Free Full Text]
43. Angel P, Allegretto EA, Okino ST, Hattori K, Boyle WJ, Hunter T, Karin M: Oncogene jun encodes a sequence-specific transactivator similar to AP-1 Nature 332:166, 1988
44.
Cleveland DW,
Lopata MA,
MacDonald RJ,
Cowan NJ,
Rutter WJ,
Kirshner M:
Number and evolutionary conservation of and tubulin and cytoplasmic -and -actin genes using specific cloned cDNA probes.
Cell
20:95,
1980[Medline]
[Order article via Infotrieve]
45.
Saleem A,
Yuan ZM,
Kufe DW,
Kharbanda S:
Activation of serine/threonine protein kinases and early growth response 1 gene expression by tumor necrosis factor in human myeloid leukemia cells.
J Immunol
154:4150,
1995[Abstract]
46.
Chauhan D,
Kharbanda S,
Ogata A,
Urashima M,
Malik N,
Frank D,
Kufe D,
Anderson KC:
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
J Exp Med
182:1801,
1995[Abstract/Free Full Text]
47.
Nagata S:
Fas/Fas ligand: A death factor and its receptor.
Adv Immunol
57:129,
1994[Medline]
[Order article via Infotrieve]
48.
Nagata S,
Goldstein P:
The Fas death factor.
Science
267:1449,
1995[Abstract/Free Full Text]
49.
Suda T,
Nagata S:
Purification and characterization of Fas-ligand that induces apoptosis.
J Exp Med
179:873,
1994[Abstract/Free Full Text]
50.
Willie AH:
Glucocorticoids induced thymocyte apoptosis is associated with endogenous endonuclease activation.
Nature
284:555,
1980[Medline]
[Order article via Infotrieve]
51.
Itoh N,
Nagata S:
A novel protein domain required for apoptosis. Mutational analysis of Fas antigen.
J Biol Chem
268:10932,
1993[Abstract/Free Full Text]
52.
Obeid LM,
Linardic CM,
Karolak LA,
Hannum YA:
Programmed cell death induced by ceramide.
Science
259:1769,
1993[Abstract/Free Full Text]
53.
Cifone MG,
Maria RD,
Rancoaiole P,
Rippo MR,
Azuma M,
Lainier LL,
Santoni A,
Testi R:
Apoptotic signaling through CD95(Fas/APO-1) activates an acidic sphingomyelinase.
J Exp Med
177:1547,
1994
54.
Enari M,
Hug H,
Nagata S:
Involvement of an ICE/CED-3 protease in Fas-mediated apoptosis.
Nature
375:78,
1995[Medline]
[Order article via Infotrieve]
55.
Los M,
Van de Craen M,
Penning LC,
Schek H,
Westendorf M,
Baeurle PA,
Droge W,
Krammer PH,
Fiers W,
Schulze-Osthoff K:
Requirement of an ICE/CED-3 protease for Fas/APO-1 mediated apoptosis.
Nature
375:81,
1995[Medline]
[Order article via Infotrieve]
56.
Buttayan R,
Olsson CA,
Pintar J,
Chang C,
Bandyk M,
Sawczuk IS:
Induction of the TRPM-2 gene in cells undergoing programmed cell death.
Mol Cell Biol
9:3473,
1989[Abstract/Free Full Text]
57.
Smeyne RJ,
Vendrell M,
Hayward M,
Baker SJ,
Miao GC,
Schilling K,
Robertson LM,
Curran T,
Morgan JI:
Continuous c-fos precedes programmed cell death in vivo.
Nature
363:166,
1993[Medline]
[Order article via Infotrieve]
58.
Angel P,
Hattori K,
Smeal T,
Karin M:
The jun protoncogene is positively autoregulated by its product, Jun/AP-1.
Cell
55:875,
1988[Medline]
[Order article via Infotrieve]
59.
Smeal T,
Binetruy B,
Mercola D,
Grover-Bardwick A,
Heidecker G,
Rapp UR,
Karin M:
Oncoprotein-mediated signaling cascade stimulates c-Jun activity by phosphorylation of serine 63 and 73.
Mol Cell Biol
12:3507,
1992[Abstract/Free Full Text]
60.
Ong F,
Nieuwkoop JAV,
Degrootswings GMJS,
Hermans J,
Harvey MS,
Kluin PM,
Kluinnelemans JC:
BCL-2 protein expression is not related to short survival in multiple myeloma.
Leukemia
9:1282,
1995[Medline]
[Order article via Infotrieve]
61.
Bataille R,
Jourdan M,
Zhang XG,
Klein B:
Serum levels of interleukin-6: A potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias.
J Clin Invest
84:2008,
1989
62.
Ludwig H,
Nachbaur DM,
Fritz E,
Krainer M,
Huber H:
Interleukin-6 is a prognostic factor in multiple myeloma.
Blood
77:2794,
1991[Free Full Text]
63.
Pelliniemi TT,
Irjala K,
Mattila K,
Pulkki K,
Rajamaki A,
Tienhaara A,
Laakso M,
Lahtinen R:
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma.
Blood
85:765,
1995[Abstract/Free Full Text]
64.
Nakafuku M,
Satoh T,
Kaziro Y:
Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active RAS-GTP complex in rat pheochromocytoma PC12 cells.
J Biol Chem
267:19448,
1992[Abstract/Free Full Text]
65.
Daeipour M,
Kumar G,
Amaral MC,
Nel AE:
Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF10.
J Immunol
150:4743,
1993[Abstract]
66.
Kumar G,
Gupta S,
Wang S,
Nel AE:
Involvement of Janus kinases, p52shc, Raf-1 and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line.
J Immunol
153:4436,
1994[Abstract]
67.
Billadeau D,
Jelinek DF,
Shah N,
LeBien TW,
Ness BV:
Introduction of an activated N-ras oncogene alters the growth characteristic of the interleukin 6-dependent myeloma cell line ANBL-6.
Cancer Res
55:3640,
1995[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton
{beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Cancer Res.,
February 1, 2009;
69(3):
1009 - 1015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ara, L. Song, H. Shimada, N. Keshelava, H. V. Russell, L. S. Metelitsa, S. G. Groshen, R. C. Seeger, and Y. A. DeClerck
Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells
Cancer Res.,
January 1, 2009;
69(1):
329 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma and A. Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors
Blood,
August 15, 2008;
112(4):
1338 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
J. Immunol.,
February 1, 2008;
180(3):
1545 - 1555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood,
July 15, 2007;
110(2):
709 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al.
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1718 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Blood,
February 1, 2007;
109(3):
1220 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al.
MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5887 - 5894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura
Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells.
Cancer Res.,
September 1, 2006;
66(17):
8796 - 8803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood,
May 15, 2006;
107(10):
4053 - 4062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Karadag, M. Zhou, and P. I. Croucher
ADAM-9 (MDC-9/meltrin-{gamma}), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the {alpha}vbeta5 integrin
Blood,
April 15, 2006;
107(8):
3271 - 3278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yan, P. Frost, Y. Shi, B. Hoang, S. Sharma, M. Fisher, J. Gera, and A. Lichtenstein
Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis
Cancer Res.,
February 15, 2006;
66(4):
2305 - 2313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Meng, Y. Yamagiwa, S. Taffetani, J. Han, and T. Patel
IL-6 activates serum and glucocorticoid kinase via p38{alpha} mitogen-activated protein kinase pathway
Am J Physiol Cell Physiol,
October 1, 2005;
289(4):
C971 - C981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Hodge, W. Xiao, B. Peng, J. C. Cherry, D. J. Munroe, and W. L. Farrar
Enforced Expression of Superoxide Dismutase 2/Manganese Superoxide Dismutase Disrupts Autocrine Interleukin-6 Stimulation in Human Multiple Myeloma Cells and Enhances Dexamethasone-Induced Apoptosis
Cancer Res.,
July 15, 2005;
65(14):
6255 - 6263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
Blood,
July 15, 2005;
106(2):
706 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
Blood,
June 1, 2005;
105(11):
4470 - 4476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sohara, H. Shimada, C. Minkin, A. Erdreich-Epstein, J. A. Nolta, and Y. A. DeClerck
Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer Cells
Cancer Res.,
February 15, 2005;
65(4):
1129 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
Blood,
January 15, 2005;
105(2):
794 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Hui, W. Zhang, W. Chen, D. Xi, B. Purow, G. C. Friedman, and H. A. Fine
Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells
Cancer Res.,
December 15, 2004;
64(24):
9115 - 9123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood,
December 15, 2004;
104(13):
4188 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yuan, F. J. Liddle, S. Mahajan, and D. A. Frank
IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor
Carcinogenesis,
November 1, 2004;
25(11):
2247 - 2255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, C. Mitsiades, R. Schlossman, N. Munshi, P. Richardson, F. E. Cotter, and K. C. Anderson
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
Blood,
October 15, 2004;
104(8):
2458 - 2466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, R. Shringarpure, L. Catley, C. Mitsiades, N. Munshi, Y. T. Tai, N. Suh, et al.
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
Blood,
April 15, 2004;
103(8):
3158 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamagiwa, C. Marienfeld, F. Meng, M. Holcik, and T. Patel
Translational Regulation of X-Linked Inhibitor of Apoptosis Protein by Interleukin-6: A Novel Mechanism of Tumor Cell Survival
Cancer Res.,
February 15, 2004;
64(4):
1293 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Oskeritzian, W. Zhao, A. L. Pozez, N. M. Cohen, M. Grimes, and L. B. Schwartz
Neutralizing Endogenous IL-6 Renders Mast Cells of the MCT Type from Lung, but Not the MCTC Type from Skin and Lung, Susceptible to Human Recombinant IL-4-Induced Apoptosis
J. Immunol.,
January 1, 2004;
172(1):
593 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al.
Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma
Cancer Res.,
December 1, 2003;
63(23):
8428 - 8436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson
Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis
J. Clin. Oncol.,
November 15, 2003;
21(22):
4239 - 4247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, L. Catley, Y. T. Tai, T. Hayashi, R. Shringarpure, et al.
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
Blood,
November 1, 2003;
102(9):
3379 - 3386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood,
June 15, 2003;
101(12):
4667 - 4679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Underhill, D. George, E. G. Bremer, and G. S. Kansas
Gene expression profiling reveals a highly specialized genetic program of plasma cells
Blood,
May 15, 2003;
101(10):
4013 - 4021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al.
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
Blood,
May 1, 2003;
101(9):
3606 - 3614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman, D. Chauhan, and K. C. Anderson
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
Blood,
January 15, 2003;
101(2):
703 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism
Blood,
October 16, 2002;
100(9):
3333 - 3343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, L. Catley, T. Hideshima, G. Li, R. Leblanc, D. Gupta, M. Sattler, P. Richardson, R. L. Schlossman, K. Podar, et al.
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
Blood,
August 28, 2002;
100(6):
2187 - 2194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana, R. G. Hughes, D. Hochhauser, and J. A. Hartley
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
Blood,
June 17, 2002;
100(1):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Greenstein, K. Ghias, N. L. Krett, and S. T. Rosen
Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies
Clin. Cancer Res.,
June 1, 2002;
8(6):
1681 - 1694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al.
NF-kappa B as a Therapeutic Target in Multiple Myeloma
J. Biol. Chem.,
May 3, 2002;
277(19):
16639 - 16647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology,
January 1, 2002;
2002(1):
214 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M.-T. Lin, C.-Y. Juan, K.-J. Chang, W.-J. Chen, and M.-L. Kuo
IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1
Carcinogenesis,
December 1, 2001;
22(12):
1947 - 1953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-h. Hsu, Y. Shi, S. Krajewski, S. Renner, M. Fisher, J. C. Reed, T. F. Franke, and A. Lichtenstein
The AKT kinase is activated in multiple myeloma tumor cells
Blood,
November 1, 2001;
98(9):
2853 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Blood,
August 1, 2001;
98(3):
795 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Grad, N. J. Bahlis, I. Reis, M. M. Oshiro, W. S. Dalton, and L. H. Boise
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
Blood,
August 1, 2001;
98(3):
805 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Blood,
January 15, 2001;
97(2):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Hjertner, H. Hjorth-Hansen, M. Borset, C. Seidel, A. Waage, and A. Sundan
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
Blood,
January 15, 2001;
97(2):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology,
January 1, 2001;
2001(1):
157 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tu, A. Gardner, and A. Lichtenstein
The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses
Cancer Res.,
December 1, 2000;
60(23):
6763 - 6770.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al.
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
Blood,
December 1, 2000;
96(12):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. E. Davies, Y.-T. Tai, S. P. Treon, B. Lin, R. L. Schlossman, P. Richardson, et al.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Blood,
November 1, 2000;
96(9):
2943 - 2950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kawamura, M. Kizaki, K. Yamato, H. Uchida, Y. Fukuchi, Y. Hattori, T. Koseki, T. Nishihara, and Y. Ikeda
Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3
Blood,
September 15, 2000;
96(6):
2005 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ogawa, T. Nishiura, K. Oritani, H. Yoshida, M. Yoshimura, Y. Okajima, J. Ishikawa, K. Hashimoto, I. Matsumura, Y. Tomiyama, et al.
Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line
Cancer Res.,
August 1, 2000;
60(15):
4262 - 4269.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Raje and K. C. Anderson
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma
Blood,
July 15, 2000;
96(2):
381 - 383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Park, J. G. Seol, E. S. Kim, J. M. Hyun, C. W. Jung, C. C. Lee, B. K. Kim, and Y. Y. Lee
Arsenic Trioxide-mediated Growth Inhibition in MC/CAR Myeloma Cells via Cell Cycle Arrest in Association with Induction of Cyclin-dependent Kinase Inhibitor, p21, and Apoptosis
Cancer Res.,
June 1, 2000;
60(11):
3065 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Blood,
April 15, 2000;
95(8):
2630 - 2636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, G. Teoh, N. Raje, S. P. Treon, Y.-T. Tai, Y. Shima, and K. C. Anderson
Characterization of Signaling Cascades Triggered by Human Interleukin-6 versus Kaposi's Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6
Clin. Cancer Res.,
March 1, 2000;
6(3):
1180 - 1189.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Teoh, Y.-T. Tai, M. Urashima, S. Shirahama, M. Matsuzaki, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, et al.
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
Blood,
February 1, 2000;
95(3):
1039 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
Blood,
January 15, 2000;
95(2):
610 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Oskeritzian, Z. Wang, J. P. Kochan, M. Grimes, Z. Du, H.-W. Chang, S. Grant, and L. B. Schwartz
Recombinant Human (rh)IL-4-Mediated Apoptosis and Recombinant Human IL-6-Mediated Protection of Recombinant Human Stem Cell Factor-Dependent Human Mast Cells Derived from Cord Blood Mononuclear Cell Progenitors
J. Immunol.,
November 1, 1999;
163(9):
5105 - 5115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Ruiter, S. F. Zerp, H. Bartelink, W. J. van Blitterswijk, and M. Verheij
Alkyl-Lysophospholipids Activate the SAPK/JNK Pathway and Enhance Radiation-induced Apoptosis
Cancer Res.,
May 1, 1999;
59(10):
2457 - 2463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. M. van den Brink, R. Kapeller, J. C. Pratt, J.-H. Chang, and S. J. Burakoff
The Extracellular Signal-regulated Kinase Pathway Is Required for Activation-induced Cell Death of T Cells
J. Biol. Chem.,
April 16, 1999;
274(16):
11178 - 11185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. L. Ma, S. Kumar, F. Gao, C. S. Louden, B. L. Lopez, T. A. Christopher, C. Wang, J. C. Lee, G. Z. Feuerstein, and T.-L. Yue
Inhibition of p38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion
Circulation,
April 6, 1999;
99(13):
1685 - 1691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rousselot, S. Labaume, J.-P. Marolleau, J. Larghero, M.-H. Noguera, J.-C. Brouet, and J.-P. Fermand
Arsenic Trioxide and Melarsoprol Induce Apoptosis in Plasma Cell Lines and in Plasma Cells from Myeloma Patients
Cancer Res.,
March 1, 1999;
59(5):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, T. Hideshima, S. Treon, G. Teoh, N. Raje, S. Yoshihimito, Y.-T. Tai, W. Li, J. Fan, J. DeCaprio, et al.
Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells
Cancer Res.,
March 1, 1999;
59(6):
1192 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sbih-Lammali, B. Clausse, H. Ardila-Osorio, R. Guerry, M. Talbot, S. Havouis, L. Ferradini, J. Bosq, T. Tursz, and P. Busson
Control of Apoptosis in Epstein Barr Virus-positive Nasopharyngeal Carcinoma Cells: Opposite Effects of CD95 and CD40 Stimulation
Cancer Res.,
February 1, 1999;
59(4):
924 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ayroldi, O. Zollo, L. Cannarile, F. D' Adamio, U. Grohmann, D. V. Delfino, and C. Riccardi
Interleukin-6 (IL-6) Prevents Activation-Induced Cell Death: IL-2-Independent Inhibition of Fas/fasL Expression and Cell Death
Blood,
December 1, 1998;
92(11):
4212 - 4219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Martins, T. J. Kottke, S. H. Kaufmann, and W. C. Earnshaw
Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis
Blood,
November 1, 1998;
92(9):
3042 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Voorzanger-Rousselot, M.-C. Favrot, and J.-Y. Blay
Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells
Blood,
November 1, 1998;
92(9):
3381 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Spets, P. Georgii-Hemming, J. Siljason, K. Nilsson, and H. Jernberg-Wiklund
Fas/APO-1 (CD95)-Mediated Apoptosis Is Activated by Interferon-gamma and Interferon-alpha in Interleukin-6 (IL-6)-Dependent and IL-6-Independent Multiple Myeloma Cell Lines
Blood,
October 15, 1998;
92(8):
2914 - 2923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, G. Teoh, M. Urashima, A. Ogata, D. Chauhan, I. J. Webb, and K. C. Anderson
Anti-Estrogens Induce Apoptosis of Multiple Myeloma Cells
Blood,
September 1, 1998;
92(5):
1749 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, G. Teoh, D. Chauhan, A. Ogata, S. Shirahama, C. Kaihara, M. Matsuzaki, H. Matsushima, M. Akiyama, Y. Yuza, et al.
MDM2 Protein Overexpression Inhibits Apoptosis of TF-1 Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Acute Myeloblastic Leukemia Cells
Blood,
August 1, 1998;
92(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-U. Simon, S. Yousefi, B. Dibbert, H. Hebestreit, M. Weber, D. R. Branch, K. Blaser, F. Levi-Schaffer, and G. P. Anderson
Role for Tyrosine Phosphorylation and Lyn Tyrosine Kinase in Fas Receptor-Mediated Apoptosis in Eosinophils
Blood,
July 15, 1998;
92(2):
547 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-h. Xu, S. Sharma, A. Gardner, Y. Tu, A. Raitano, C. Sawyers, and A. Lichtenstein
Interleukin-6-Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway
Blood,
July 1, 1998;
92(1):
241 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hebestreit, B. Dibbert, I. Balatti, D. Braun, A. Schapowal, K. Blaser, and H.-U. Simon
Disruption of Fas Receptor Signaling by Nitric Oxide in Eosinophils
J. Exp. Med.,
February 2, 1998;
187(3):
415 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, P. Pandey, A. Ogata, G. Teoh, N. Krett, R. Halgren, S. Rosen, D. Kufe, S. Kharbanda, and K. Anderson
Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells
J. Biol. Chem.,
November 28, 1997;
272(48):
29995 - 29997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, J. A. DeCaprio, D. Chauhan, G. Teoh, A. Ogata, S. P. Treon, Y. Hoshi, and K. C. Anderson
p16INK4A Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells
Blood,
November 15, 1997;
90(10):
4106 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, B. P. Chen, S. Chen, G. S. Pinkus, R. T. Bronson, D. A. Dedera, Y. Hoshi, G. Teoh, A. Ogata, S. P. Treon, et al.
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Blood,
July 15, 1997;
90(2):
754 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Vincent, M. Jourdan, M.-S. Sy, B. Klein, and N. Mechti
Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein
J. Biol. Chem.,
April 27, 2001;
276(18):
14728 - 14736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract